Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

DiCE

- PMLiVE

Merck joins biosimilar Lantus race

Will work with Samsung to develop version of Sanofi's diabetes medicine

- PMLiVE

Interview: Laure Thibaud, Sanofi

Sanofi’s head of communications talks about her mission to build a team fit for the modern age

Sanofi reception

Sanofi has been light on product launches, says CEO

Drugs launched since 2009 contribute less than €1bn to 2013 turnover

- PMLiVE

NIH forges $230m research alliance with pharma

Brings 10 pharma companies together to speed up research in Alzheimer’s, diabetes and arthritis

Sanofi reception

Sanofi sues Lilly over insulin patents

Challenges development of Lantus biosimilar

- PMLiVE

NICE recommends Sanofi’s oral MS drug

Aubagio backed for NHS use in England and Wales

Sanofi reception

Sanofi forms antibiotic research partnership

Will team up with Germany’s Fraunhofer-Gesellschaft to develop naturally-derived substances

Sanofi reception

Sanofi strikes $700m rare diseases deal

Company's Genzyme division will obtain significant rights to Alnylam’s pipeline of orphan drugs

- PMLiVE

Genzyme shocked by FDA’s rejection of Lemtrada

US regulator refuses to approve MS drug on safety grounds

- PMLiVE

ABPI reprimands for four pharma firms

Allergan, Shire Pharmaceuticals, Gedeon Richter and Sanofi breach Code of Practice

- PMLiVE

Sanofi’s Aubagio backed by NICE

Oral MS drug recommended for NHS use in England and Wales

National Institute for Health and Care Excellence NICE logo

NICE wants more info on Genzyme’s MS drug

UK health guidance body turns down Lemtrada in draft guidance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links